ALK and RET inhibitors promote HLA class I antigen presentation and unmask new antigens within the tumor immunopeptidome

T cell immunotherapies are often thwarted by the limited presentation of tumor-specific antigens abetted by the downregulation of human leukocyte antigen (HLA). We showed that drugs inhibiting ALK and RET produced dose-related, increases in cell surface HLA in tumor cells bearing these mutated kinas...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer Immunol Res
Hauptverfasser: Oh, Claire Y., Klatt, Martin G., Bourne, Christopher, Dao, Tao, Dacek, Megan M., Brea, Elliott J., Mun, Sung Soo, Chang, Aaron Y., Korontsvit, Tatyana, Scheinberg, David A.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2019
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6891198/
https://ncbi.nlm.nih.gov/pubmed/31540894
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-19-0056
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge